Introduction Numbers of gonorrhoea cases have increased, and the World Health Organization has estimated 106 million new cases in adults worldwide for 2008, which was 21% higher than numbers for 2005 [1]. At the same time, rising rates of antimicrobial resistance of its causative agent, Neisseria gonorrhoeae, have been reported in many parts of the world including Europe, even against the third-generation cephalosporins, cefixime and ceftriaxone [2,3]. For this reason, cefixime alone is no longer recommended as single-drug treatment for gonorrhoea in Europe or the United States [4,5]. The European Gonococcal Antimicrobial Surveillance Programme (EURO-GASP) was established by 12 European countries in 2004 in response to the emerging antimicrobial resistance of N. gonorrhoeae, as part of the European Surveillance of Sexually Transmitted Infections Project [6]. In 2016, EURO-GASP has participation from laboratories from 21 European Union/European Economic Area countries, which regularly report gonorrhoea susceptibility testing results and epidemiological surveillance data, and submit gonococcal isolates for centralised testing or participate in decentralised testing. Since 2009, EURO-GASP has been coordinated by the European Centre for Disease Prevention and Control (ECDC). Resistance data have been published regularly and in a timely manner [7,8], but the numbers of isolates tested per country are relatively low (between 10 and 251 in 2011 [8]) and therefore most likely not representative of the epidemiological situation of the individual countries. As cases of gonorrhoea or antimicrobial resistance patterns of N. gonorrhoeae isolates are not subject to reporting in Germany, data regarding current antimicrobial susceptibility and its development over time are scarce. Only three individual studies have addressed this issue in the past 10 years. Abraham et al. analysed 50 isolates collected between 2001 and 2010 in Dresden, Saxony [9], while Horn and colleagues have reported the results of a nationwide surveillance study conducted by the Paul-Ehrlich-Society of Chemotherapy in 2010/2011 in which 213 isolates submitted by 23 laboratories were analysed [10]. Additionally, minimum inhibitory concentrations (MICs) of selected antibiotics for 65 N. gonorrhoeae isolates collected in 2004/2005 in southern Germany have been reported [11]. None of these studies has reported cephalosporin-resistant N. gonorrhoeae isolates. Data from EURO-GASP, however, have provided evidence for the presence of cephalosporin-resistant N. gonorrhoeae isolates in Germany, too [7,8]; in fact, an Austrian patient with a cefixime-resistant N. gonorrhoeae isolate acquired his infection in Munich, south Germany [12]. To gain more information on the antimicrobial susceptibility of N. gonorrhoeae in Germany and elucidate possible changes in antimicrobial resistance occurring over time, we analysed the susceptibility patterns of all N. gonorrhoeae isolates identified and tested in our laboratory between 2004 and 2015 (n = 434). Since age and sex have been identified as risk factors for harbouring antimicrobial-resistant N. gonorrhoeae isolates [13,14], we additionally analysed our data regarding these parameters. Unfortunately, the study design chosen did not provide information regarding other possible risk factors, e.g. working as professional sex worker or being a man who has sex with men (MSM).
